A laboratory developed test (LDT) is a type of in vitro diagnostic test that is designed and used within a single laboratory. These tests can be utilized to estimate or distinguish an extensive assortment of analytes materials such as proteins, chemical compounds like glucose or cholesterol, or DNA, from a specimen received from human anatomy. The expansion of automated in vitro diagnostics (IVD) methods for labs and dispensaries to render precise, and error-free analysis is anticipated to fuel the increment.
Quest Diagnostics Incorporated and F. HOFFMANN-LA ROCHE LTD Company LLC — Notable Market Players in Laboratory Developed Test Market
Leading players operating in the laboratory developed test market are adopting various growth strategies such as product launches, approvals, partnerships, and business planning. These strategies help them expand their business in the global market. Quest Diagnostics Incorporated, F. HOFFMANN-LA ROCHE LTD., QIAGEN, Illumina, Inc., Eurofins Scientific, Biodesix, Adaptive Biotechnologies, Biotheranostics, Rosetta Genomics Ltd., Guardant Health are among the leading companies operating in the market.
A few growth strategies adopted by the players operating in the laboratory developed test market are listed below:
|Month and Year||Description|
|August-2021||eMed, a telehealth company democratizing healthcare through digital-point-of-care solutions, and Quest Diagnostics the world’s leading provider of diagnostic information services, are collaborated to bring clinician-guided rapid antigen testing for COVID-19 to employers seeking to foster safer environments by decreasing the risk of COVID-19 exposure in their workplaces.|
|July-2021||CLX Health, developer of cloud-based solutions to manage the COVID-19 testing ecosystem with their TrustAssure Global Network, announced a collaboration with Quest Diagnostics the world’s leading provider of diagnostic information services, to provide access to COVID-19 molecular diagnostic testing (PCR/NAAT) for people seeking to attend live events nationwide or travel from the United States to destinations around the world.|
|June-2021||Biodesix, a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help protect, match, and share health data.|
|May-2021||Guardant360 CDx Received FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations|
|Febraury-2021||Adaptive Biotechnologies Corporation announced the launch of T-Detect COVID, the first clinical T-cell based test to confirm recent or prior COVID-19 infection.|
|June-2021||Roche announced it has received CE mark for its SARS-CoV-2 Antigen Self-Test Nasal for at-home testing. The test available in countries accepting the CE mark through pharmacies and other locations, in packs of five tests.|
|September-2020||llumina, Inc. and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction.|
|December-2020||Eurofins launched EmpowerDX SARS CoV 2 RT PCR test with at home sampling option after it received an Emergency Use Authorization (EUA) by the FDA.|